Larimar Therapeutics Inc LRMR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $3.60
- Day Range
- $3.43–3.73
- 52-Week Range
- $2.22–6.42
- Bid/Ask
- $3.36 / $3.51
- Shares Outstanding
- 103.88M
- Market Cap
- $360.47M
- Volume/Avg
- 2M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 71
- Website
- https://www.larimartx.com
Valuation
|
Metric
|
LRMR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.37 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LRMR
|
|---|---|
Quick Ratio | 4.21 |
Current Ratio | 4.29 |
Interest Coverage | — |
Quick Ratio
LRMR
Profitability
|
Metric
|
LRMR
|
|---|---|
Return on Assets (Normalized) | −92.16% |
Return on Equity (Normalized) | −124.25% |
Return on Invested Capital (Normalized) | −120.17% |
Return on Assets
LRMR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Fxlfwdgtb | Rhmfggr | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Cpmmshqv | Rlcmy | $64B | |||
| argenx SE ADR
ARGX
| Gkysjxlky | Xft | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Wfbtfmxm | Mtvvtqv | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Cdvptjrlk | Ncksxw | $24B | |||
| BioNTech SE ADR
BNTX
| Nlcdvzq | Fcjgf | $23B | |||
| Incyte Corp
INCY
| Xtvzdswmm | Nzrg | $22B | |||
| Moderna Inc
MRNA
| Zbssqns | Hlgt | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Xqrcdwtk | Dhqvt | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Tbfrkdkb | Fvzp | $13B |
United States